Media release

From: University of Technology Sydney (UTS)

New research from the University of Technology Sydney (UTS) has found that pathogens that form biofilms can evolve to survive nanosilver treatment.  The study is the first to demonstrate that long-term nanosilver treatment can increase the risk of recurrent infections.

The research is published in the prestigious Journal of Nanobiotechnology.

Nanosilver is a potent antimicrobial that is currently used in medical devices such as internal catheters, as well as wound dressings, in particular for burn wounds, to fight or prevent infections. It is also one of the most commercialised antimicrobial nanoparticles, and has been incorporated into consumer products from personal care products, such as soaps and toothpaste, to washing machines and fridges, even children’s products, such as in kids socks to prevent odour.

Researchers at UTS’s iThree Institute studied nanosilver adaptation phenomena in the bacterium Pseudomonas aeruginosa, in its biofilm form of growth, and observed a novel adaptation mechanism not seen in previous planktonic growth studies. Following prolonged treatment, nanosilver killed 99.99% of the bacterial population with only 0.01% cells surviving for longer. This minute fraction of ‘persisters’ resumed normal growth upon discontinuation of the nanoparticle treatment.

“Understanding how pathogens develop adaptation mechanisms to nanoparticles is key in our effort to overcome the phenomena, including in biofilms as the major form of growth of pathogenic bacteria. This is to protect the efficacy of important alternative antimicrobials, like nanosilver, in this era of increasing antibiotic resistance,” said lead author Dr Cindy Gunawan.

The study first author, Dr Riti Mann, said the research findings will also help develop strategies on the better management of nanoparticle use as antimicrobials, in particular those that involving long-term exposures.

“Based on this study, we recommend monitoring patients not only during, but also after prolonged use of nanoparticle treatment for safeguarding against recurrent infections.

“The scientific evidence that bacteria can adapt to nanoparticles means we need effective regulation of the use of nanoparticles, with clear risks versus benefits assessment and clear antimicrobial targets. With limited development of new effective antibiotics over the past decades, we need to preserve the efficacy of the alternative antimicrobials to fight untreatable infections, saving lives and billions of dollars in healthcare,” said Dr Gunawan.

The bacterium used in the study, Pseudomonas aeruginosa, often attach themselves on catheter surfaces, as well as to wounds and lung linings, growing biofilms, which can be difficult to control.